Literature DB >> 30351168

Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors.

Maxime J Jean1, Guillaume Fiches2, Tsuyoshi Hayashi3, Jian Zhu2.   

Abstract

Since the implementation of combination antiretroviral therapy (cART), rates of HIV type 1 (HIV-1) mortality, morbidity, and newly acquired infections have decreased dramatically. In fact, HIV-1-infected individuals under effective suppressive cART approach normal life span and quality of life. However, long-term therapy is required because the virus establish a reversible state of latency in memory CD4+ T cells. Two principle strategies, namely "shock and kill" approach and "block and lock" approach, are currently being investigated for the eradication of these HIV-1 latent reservoirs. Actually, both of these contrasting approaches are based on the use of small-molecule compounds to achieve the cure for HIV-1. In this review, we discuss the recent progress that has been made in designing and developing small-molecule compounds for both strategies.

Entities:  

Keywords:  HIV cure; HIV latency; latency-promoting agents; latency-reversing agents; “block and lock”; “shock and kill”

Mesh:

Substances:

Year:  2018        PMID: 30351168      PMCID: PMC6343200          DOI: 10.1089/AID.2018.0153

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  212 in total

1.  Inhibition of human immunodeficiency virus type 1 tat-trans-activation-responsive region interaction by an antiviral quinolone derivative.

Authors:  Sara Richter; Cristina Parolin; Barbara Gatto; Claudia Del Vecchio; Egidio Brocca-Cofano; Arnaldo Fravolini; Giorgio Palù; Manlio Palumbo
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

2.  HIV and AIDS--United States, 1981-2000.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2001-06-01       Impact factor: 17.586

3.  Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy.

Authors:  Laura E Jones; Alan S Perelson
Journal:  J Acquir Immune Defic Syndr       Date:  2007-08-15       Impact factor: 3.731

4.  Reactivation of latent HIV-1 by new semi-synthetic ingenol esters.

Authors:  Diego Pandeló José; Koen Bartholomeeusen; Rodrigo Delvecchio da Cunha; Celina Monteiro Abreu; Jan Glinski; Thais Barbizan Ferreira da Costa; Ana Flávia Mello Bacchi Rabay; Luiz Francisco Pianowski Filho; Lech W Dudycz; Udaykumar Ranga; Boris Matija Peterlin; Luiz Francisco Pianowski; Amilcar Tanuri; Renato Santana Aguiar
Journal:  Virology       Date:  2014-07-09       Impact factor: 3.616

5.  Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection.

Authors:  A C Collier; R W Coombs; M A Fischl; P R Skolnik; D Northfelt; P Boutin; C J Hooper; L D Kaplan; P A Volberding; L G Davis; D R Henrard; S Weller; L Corey
Journal:  Ann Intern Med       Date:  1993-10-15       Impact factor: 25.391

6.  T cell receptor signalling.

Authors:  J Lin; A Weiss
Journal:  J Cell Sci       Date:  2001-01       Impact factor: 5.285

7.  HIV Latency Is Established Directly and Early in Both Resting and Activated Primary CD4 T Cells.

Authors:  Leonard Chavez; Vincenzo Calvanese; Eric Verdin
Journal:  PLoS Pathog       Date:  2015-06-11       Impact factor: 6.823

8.  CpG methylation controls reactivation of HIV from latency.

Authors:  Jana Blazkova; Katerina Trejbalova; Françoise Gondois-Rey; Philippe Halfon; Patrick Philibert; Allan Guiguen; Eric Verdin; Daniel Olive; Carine Van Lint; Jiri Hejnar; Ivan Hirsch
Journal:  PLoS Pathog       Date:  2009-08-21       Impact factor: 6.823

9.  New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.

Authors:  C Korin Bullen; Gregory M Laird; Christine M Durand; Janet D Siliciano; Robert F Siliciano
Journal:  Nat Med       Date:  2014-03-23       Impact factor: 53.440

10.  The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication.

Authors:  Victoria E Walker-Sperling; Christopher W Pohlmeyer; Patrick M Tarwater; Joel N Blankson
Journal:  EBioMedicine       Date:  2016-04-18       Impact factor: 8.143

View more
  8 in total

1.  HSF1 Activation Can Restrict HIV Replication.

Authors:  Emmanuel E Nekongo; Anna I Ponomarenko; Mahender B Dewal; Vincent L Butty; Edward P Browne; Matthew D Shoulders
Journal:  ACS Infect Dis       Date:  2020-06-10       Impact factor: 5.084

Review 2.  Targeting HIV-1 proviral transcription.

Authors:  Alex Olson; Binita Basukala; Wilson W Wong; Andrew J Henderson
Journal:  Curr Opin Virol       Date:  2019-08-29       Impact factor: 7.121

Review 3.  Cat and Mouse: HIV Transcription in Latency, Immune Evasion and Cure/Remission Strategies.

Authors:  Aurélie Delannoy; Mikaël Poirier; Brendan Bell
Journal:  Viruses       Date:  2019-03-18       Impact factor: 5.048

Review 4.  Novel Approaches Towards a Functional Cure of HIV/AIDS.

Authors:  Lucia Bailon; Beatriz Mothe; Lance Berman; Christian Brander
Journal:  Drugs       Date:  2020-06       Impact factor: 9.546

5.  Screening for gene expression fluctuations reveals latency-promoting agents of HIV.

Authors:  Yiyang Lu; Kathrin Bohn-Wippert; Patrick J Pazerunas; Jennifer M Moy; Harpal Singh; Roy D Dar
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-16       Impact factor: 11.205

Review 6.  Therapeutic potential of inhibiting histone 3 lysine 27 demethylases: a review of the literature.

Authors:  Jeries Abu-Hanna; Jigisha A Patel; Evangelos Anastasakis; Richard Cohen; Lucie H Clapp; Marilena Loizidou; Mohammad M R Eddama
Journal:  Clin Epigenetics       Date:  2022-08-01       Impact factor: 7.259

Review 7.  Forging a Functional Cure for HIV: Transcription Regulators and Inhibitors.

Authors:  Sonia Mediouni; Shuang Lyu; Susan M Schader; Susana T Valente
Journal:  Viruses       Date:  2022-09-07       Impact factor: 5.818

8.  Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform.

Authors:  Eytan Herzig; Kaman Chan Kim; Thomas A Packard; Noam Vardi; Roland Schwarzer; Andrea Gramatica; Steven G Deeks; Steven R Williams; Kyle Landgraf; Nigel Killeen; David W Martin; Leor S Weinberger; Warner C Greene
Journal:  Cell       Date:  2019-10-24       Impact factor: 41.582

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.